anti-Nipah_223
| anti-Nipah_ID | anti-Nipah_223 |
| anti-Nipah Drug | PKC Inhibitor |
| Nipah virus strain | NiV (Malaysia-1999) |
| Approaches used to test anti-Nipah activity | Experimental |
| Methods used to test anti-Nipah activity | in-vitro |
| Models used to test anti-Nipah activity | Vero |
| Mode of infection to test anti-Nipah activity | Adsorption |
| Viral titer to test anti-Nipah activity | 1000 TCID50 |
| Mode of Drug delivery for anti-Nipah activity | Culture |
| Time of Drug delivery for anti-Nipah activity | During infection |
| Duration of Drug delivery for anti-Nipah activity | Overnight |
| Drug concentration used to test anti-Nipah activity | 1481.75 μM |
| Assays used to test anti-Nipah activity | Immunolabeling assay |
| anti-Nipah activity | No significant difference [Inhibitory concentration (50 %)] |
| Cytotoxicity of anti-Nipah compounds | 1848.3 _M |
| References | Aljofan M, Lo MK, Rota PA, Michalski WP, Mungall BA Off Label Antiviral Therapeutics for Henipaviruses: New Light Through Old Windows. J Antivir Antiretrovir. 2010 Jan 1;2(1):1-10. |
| Comments | Seven compounds inhibited virus replication in the micromolar range while the remaining compounsd also inhibited virus replication but only at millimolar concentrations. Pretreatment experiments with various calcium chelators, channel antagonists or endoplasmic reticulum release inhibitors supported a calcium mediated mechanism of action for five of these compounds. The mechanism of antiviral action for the remaining three compounds is currently unknown. |